Femasys $30M Private Placement Financing

Femasys Inc., a biomedical company developing fertility and non-surgical permanent birth control solutions, announced on August 7, 2026 that it entered into a securities purchase agreement for a $30 million private placement with accredited investors. The financing was led by Nantahala Capital Management, with participation from Rosalind Advisors and members of Femasys' management team. The company is selling approximately 9.37 million shares of common stock and pre-funded warrants, along with accompanying warrants to purchase up to 18.75 million shares. The purchase price is $3.20 per share and accompanying warrants, and $3.1999 per pre-funded warrant and accompanying warrants. If all warrants are exercised for cash, Femasys could receive up to an additional $60 million. The milestone warrants become exercisable after 12 months and are subject to revenue and share price milestones. The private placement is expected to close on or around August 10, 2026. Laidlaw & Company (UK) Ltd. acted as placement agent, and Lake Street Capital Markets served as financial advisor. Femasys plans to use the proceeds to strengthen its balance sheet, support commercialization of its fertility portfolio, and advance the U.S. FemBloc clinical and regulatory program.